MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Rhea-AI Summary

MannKind (Nasdaq: MNKD) will host a conference call on May 29, 2026 at 4:30 p.m. Eastern to discuss the recent FDA approval of Afrezza for children and adolescents aged 6 and older with diabetes. A live webcast and 90-day replay will be available on its investor website.

AI-generated analysis. Not financial advice.

News Market Reaction – MNKD

+3.57% 1.5x vol

9 alerts

+3.57% News Effect

+2.4% Peak in 18 min

+$42M Valuation Impact

$1.21B Market Cap

1.5x Rel. Volume

On the day this news was published, MNKD gained 3.57%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $42M to the company's valuation, bringing the market cap to $1.21B at that time. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza^® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

MANNKIND is a registered trademark of MannKind Corporation.

MannKind Contacts:
Investor Relations
Kate Miranda
Email: ir@mnkd.com

Media Relations
Christie Iacangelo
Email: media@mnkd.com

FAQ

When is MannKind's (MNKD) conference call about Afrezza pediatric FDA approval?

The conference call is scheduled for May 29, 2026 at 4:30 p.m. Eastern. According to MannKind, management will discuss FDA approval of Afrezza for children and adolescents aged 6 and older living with diabetes during this call.

How can investors access MannKind's May 29, 2026 Afrezza pediatric approval webcast?

Investors can access the live audio webcast via MannKind's investor relations events and presentations webpage. According to MannKind, links to the webcast and recorded versions will be available directly at https://investors.mannkindcorp.com/events-and-presentations for convenient online listening.

Will a replay of MannKind's Afrezza pediatric approval conference call be available?

Yes, a recorded version of the conference call will be available. According to MannKind, replays of the Afrezza pediatric FDA approval discussion will remain on the company’s investor website for approximately 90 days following the conference, allowing investors to listen later.

Who will present on MannKind's May 29, 2026 Afrezza pediatric approval call?

The call will feature CEO Michael Castagna, PharmD, and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. According to MannKind, these executives will discuss details of the FDA approval for pediatric Afrezza use.

What Afrezza FDA approval will MannKind discuss on the May 29, 2026 call?

MannKind will discuss the FDA approval of Afrezza for children and adolescents aged 6 and older with diabetes. According to MannKind, this conference call will focus on this new pediatric use and its implications for patients and the company.